Cargando…
(18)F-FDG PET/CT for staging and response assessment of primary parotid MALT lymphoma with multiple sites involvement: A case report
RATIONALE: Mucosa-associated lymphoid tissue (MALT) lymphoma is an extranodal low-grade B cell lymphoma that generally exhibits an indolent clinical course. Currently, the application of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) in MALT lymphoma is...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380729/ https://www.ncbi.nlm.nih.gov/pubmed/30702589 http://dx.doi.org/10.1097/MD.0000000000014270 |
_version_ | 1783396347040235520 |
---|---|
author | Ren, Yixuan Huang, Lele Han, Yuping Cui, Zhencun Li, Jicheng Dong, Chi Liu, Jiangyan |
author_facet | Ren, Yixuan Huang, Lele Han, Yuping Cui, Zhencun Li, Jicheng Dong, Chi Liu, Jiangyan |
author_sort | Ren, Yixuan |
collection | PubMed |
description | RATIONALE: Mucosa-associated lymphoid tissue (MALT) lymphoma is an extranodal low-grade B cell lymphoma that generally exhibits an indolent clinical course. Currently, the application of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) in MALT lymphoma is still controversial. Herein, we reported a case of using (18)F-FDG PET/CT for staging and response assessment of primary parotid MALT lymphoma with multiple sites involvement. As far as we know, there are no similar case reports have been published before. PATIENT CONCERNS: A 71-year-old woman, who received mass resection twice during the past 2 years due to the repeatedly relapse of facial painless masses and diagnosed as reactive lymphoid hyperplasia by pathologic tests. However, the pathological diagnosis was then changed to primary parotid MALT lymphoma after left parotidectomy operation because of a new mass found in her left parotid. Four months later, the right eyelid of the patient swelled with a blurred vision. Then, (18)F-FDG PET/CT scan was performed for staging, and the imaging results showed an abnormal increase of (18)F-FDG uptake in multiple sites including bilateral ocular adnexal, lungs, pleura, occipital subcutaneous tissue, left kidney, and lymph nodes. DIAGNOSES: The patient was diagnosed as primary parotid MALT lymphoma with Ann Arbor stage of IVA based on the (18)F-FDG PET/CT findings. INTERVENTIONS: The patient received 4 cycles of chemotherapy, followed by a partial metabolic remission (PMR), which was determined by interim (18)F-FDG PET/CT, and finally additional 2 cycles of chemotherapy. OUTCOMES: The follow-up study illustrated that the patient had been alive and doing well at 12 months after chemotherapy. LESSONS: Although MALT lymphoma normally localizes in the primary organs, the involvement of multiple organs and lymph nodes is possible. The use of PET/CT demonstrated significant clinical values in the accurate staging and response assessment of (18)F-FDG-avid MALT lymphoma. It is potentially useful for indicating the progress and transformation of MALT lymphoma, and guidance in localization of pathological biopsy. It is also helpful for clinicians to choose reasonable treatment strategy and improve the prognosis of patients. |
format | Online Article Text |
id | pubmed-6380729 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-63807292019-03-04 (18)F-FDG PET/CT for staging and response assessment of primary parotid MALT lymphoma with multiple sites involvement: A case report Ren, Yixuan Huang, Lele Han, Yuping Cui, Zhencun Li, Jicheng Dong, Chi Liu, Jiangyan Medicine (Baltimore) Research Article RATIONALE: Mucosa-associated lymphoid tissue (MALT) lymphoma is an extranodal low-grade B cell lymphoma that generally exhibits an indolent clinical course. Currently, the application of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) in MALT lymphoma is still controversial. Herein, we reported a case of using (18)F-FDG PET/CT for staging and response assessment of primary parotid MALT lymphoma with multiple sites involvement. As far as we know, there are no similar case reports have been published before. PATIENT CONCERNS: A 71-year-old woman, who received mass resection twice during the past 2 years due to the repeatedly relapse of facial painless masses and diagnosed as reactive lymphoid hyperplasia by pathologic tests. However, the pathological diagnosis was then changed to primary parotid MALT lymphoma after left parotidectomy operation because of a new mass found in her left parotid. Four months later, the right eyelid of the patient swelled with a blurred vision. Then, (18)F-FDG PET/CT scan was performed for staging, and the imaging results showed an abnormal increase of (18)F-FDG uptake in multiple sites including bilateral ocular adnexal, lungs, pleura, occipital subcutaneous tissue, left kidney, and lymph nodes. DIAGNOSES: The patient was diagnosed as primary parotid MALT lymphoma with Ann Arbor stage of IVA based on the (18)F-FDG PET/CT findings. INTERVENTIONS: The patient received 4 cycles of chemotherapy, followed by a partial metabolic remission (PMR), which was determined by interim (18)F-FDG PET/CT, and finally additional 2 cycles of chemotherapy. OUTCOMES: The follow-up study illustrated that the patient had been alive and doing well at 12 months after chemotherapy. LESSONS: Although MALT lymphoma normally localizes in the primary organs, the involvement of multiple organs and lymph nodes is possible. The use of PET/CT demonstrated significant clinical values in the accurate staging and response assessment of (18)F-FDG-avid MALT lymphoma. It is potentially useful for indicating the progress and transformation of MALT lymphoma, and guidance in localization of pathological biopsy. It is also helpful for clinicians to choose reasonable treatment strategy and improve the prognosis of patients. Wolters Kluwer Health 2019-02-01 /pmc/articles/PMC6380729/ /pubmed/30702589 http://dx.doi.org/10.1097/MD.0000000000014270 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 |
spellingShingle | Research Article Ren, Yixuan Huang, Lele Han, Yuping Cui, Zhencun Li, Jicheng Dong, Chi Liu, Jiangyan (18)F-FDG PET/CT for staging and response assessment of primary parotid MALT lymphoma with multiple sites involvement: A case report |
title | (18)F-FDG PET/CT for staging and response assessment of primary parotid MALT lymphoma with multiple sites involvement: A case report |
title_full | (18)F-FDG PET/CT for staging and response assessment of primary parotid MALT lymphoma with multiple sites involvement: A case report |
title_fullStr | (18)F-FDG PET/CT for staging and response assessment of primary parotid MALT lymphoma with multiple sites involvement: A case report |
title_full_unstemmed | (18)F-FDG PET/CT for staging and response assessment of primary parotid MALT lymphoma with multiple sites involvement: A case report |
title_short | (18)F-FDG PET/CT for staging and response assessment of primary parotid MALT lymphoma with multiple sites involvement: A case report |
title_sort | (18)f-fdg pet/ct for staging and response assessment of primary parotid malt lymphoma with multiple sites involvement: a case report |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380729/ https://www.ncbi.nlm.nih.gov/pubmed/30702589 http://dx.doi.org/10.1097/MD.0000000000014270 |
work_keys_str_mv | AT renyixuan 18ffdgpetctforstagingandresponseassessmentofprimaryparotidmaltlymphomawithmultiplesitesinvolvementacasereport AT huanglele 18ffdgpetctforstagingandresponseassessmentofprimaryparotidmaltlymphomawithmultiplesitesinvolvementacasereport AT hanyuping 18ffdgpetctforstagingandresponseassessmentofprimaryparotidmaltlymphomawithmultiplesitesinvolvementacasereport AT cuizhencun 18ffdgpetctforstagingandresponseassessmentofprimaryparotidmaltlymphomawithmultiplesitesinvolvementacasereport AT lijicheng 18ffdgpetctforstagingandresponseassessmentofprimaryparotidmaltlymphomawithmultiplesitesinvolvementacasereport AT dongchi 18ffdgpetctforstagingandresponseassessmentofprimaryparotidmaltlymphomawithmultiplesitesinvolvementacasereport AT liujiangyan 18ffdgpetctforstagingandresponseassessmentofprimaryparotidmaltlymphomawithmultiplesitesinvolvementacasereport |